Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 192

Sort by

Sort Order Select

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood (2024) 144 (19): 2063–2066.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

Jon Celay, Miriam Recalde, María Victoria Revuelta, Marta Larrayoz, Sara Rodriguez, Maria J Garcia-Barchino, Jennifer R. Chapman-Fredricks, Teresa Lozano, Juan J Lasarte, Ming Q. Du, Izidore S. Lossos, Sergio Roa, Aldo Roccaro, Miguel Canales, Felipe Prosper, Bruno Paiva, Leandro Cerchietti, Jose A. Martinez-Climent

Blood (2023) 142 (Supplement 1): 431.

https://doi.org/10.1182/blood-2023-173394

Published: 2023

Journal Articles

Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium

Jonathan R Day, Melissa C. Larson, Carla Casulo, Urshila Durani, Yucai Wang, Dai Chihara, Loretta J. Nastoupil, Brad S. Kahl, Peter Martin, Izidore S. Lossos, Jason T. Romancik, Amy Ayers, Richard Burack, Thomas M. Habermann, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Brian K. Link

Blood (2023) 142 (Supplement 1): 3111.

https://doi.org/10.1182/blood-2023-179650

Published: 2023

Journal Articles

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6 ) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

Blood (2023) 142 (Supplement 1): 67.

https://doi.org/10.1182/blood-2023-190316

Published: 2023

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

The FLIPI24 Prognostic Model Identifies Poor Outcomes in Non-Immunochemotherapy Treated Patients with Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2023-186684

Published: 2023

Journal Articles

Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma - a Phase 2 Study

Juan Pablo Alderuccio, Alvaro J. Alencar, Jonathan H. Schatz, Russ Kuker, Georgio Pongas, Isildinha M. Reis, Jay Y. Spiegel, Laura Medina Andara, Lazaros J. Lekakis, Joseph S. Gyedu, Jose Sandoval-Sus, Amer M. Beitinjaneh, Nathalie Padron, Izidore S. Lossos, Joseph D. Rosenblatt, David S. Lessen, Craig H. Moskowitz

Blood (2023) 142 (Supplement 1): 984.

https://doi.org/10.1182/blood-2023-178825

Published: 2023

Journal Articles

The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma

Matthew J. Maurer, Arushi Khurana, Umar Farooq, Jason T. Romancik, Jonathan W. Friedberg, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Dai Chihara, Andrew L. Feldman, Sergei Syrbu, David L Jaye, Elliot Cahn, Thomas M. Habermann, Brian K. Link, James R. Cerhan, Christopher R. Flowers, Loretta J. Nastoupil, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4512.

https://doi.org/10.1182/blood-2023-187350

Published: 2023

Journal Articles

Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

Blood (2023) 142 (Supplement 1): 309.

https://doi.org/10.1182/blood-2023-174497

Published: 2023

Journal Articles

LEO Consortium for Real World Evidence (CReWE): Outcomes after Second-Line Therapy in Large B-Cell Lymphoma By Treatment Era

Blood (2023) 142 (Supplement 1): 307.

https://doi.org/10.1182/blood-2023-186270

Published: 2023

Journal Articles

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Blood (2023) 142 (Supplement 1): 3761.

https://doi.org/10.1182/blood-2023-188382

Published: 2023

Journal Articles

Risk of Transformation By Frontline Management in Follicular Lymphoma and Marginal Zone Lymphoma: A US Population-Based Analysis

Jorge A Florindez, Dai Chihara, Isildinha M. Reis, Izidore S. Lossos, Juan Pablo Alderuccio

Blood (2023) 142 (Supplement 1): 383.

https://doi.org/10.1182/blood-2023-185313

Published: 2023

Journal Articles

A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma

Asaad Trabolsi, Narendranath Epperla, Kaitlin Annunzio, Dan Morgenstern Kaplan, Peter Doukas, Frederique St-Pierre, Brittany McCall, Lindsey Fitzgerald, Sunwoo Han, Isildinha M. Reis, Jennifer Rose Chapman-Fredricks, Khaled Alhamad, Thomas Ollila, Reem Karmali, Izidore S. Lossos, Juan Pablo Alderuccio

Blood (2023) 142 (Supplement 1): 3770.

https://doi.org/10.1182/blood-2023-173905

Published: 2023

Journal Articles

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Blood (2023) 142 (Supplement 1): 2395.

https://doi.org/10.1182/blood-2023-187056

Published: 2023

Journal Articles

Predictors and Timing of Venous Thromboembolism in Lymphoma

Asaad Trabolsi, Thomas Plate, IV, Rachel S. Kronenfeld, Leticia E. Campoverde, Dan Morgenstern Kaplan, Alyssa Mercadel, Michael Caballero, Wei Zhao, Izidore S. Lossos, Craig H. Moskowitz, Gerald A. Soff

Blood (2023) 142 (Supplement 1): 2642.

https://doi.org/10.1182/blood-2023-173903

Published: 2023

Journal Articles

Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study

Blood (2023) 142 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2023-180318

Published: 2023

Journal Articles

Cumulative Incidence, Predictors, and Outcomes of Transformation to Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Patients with Marginal Zone Lymphoma

Côme Bommier, Brian K. Link, Brianna Gysbers, Matthew J. Maurer, Melissa C. Larson, Arushi Khurana, Yucai Wang, Carrie Thompson, Dai Chihara, Juan Pablo Alderuccio, Jean L. Koff, Izidore S. Lossos, Grzegorz S. Nowakowski, Andrew L. Feldman, Thomas M. Habermann, Rebecca L. King, James R. Cerhan

Blood (2023) 142 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2023-186626

Published: 2023

Journal Articles

PET/CT Enables Appropriate Staging in Extranodal Marginal Zone Lymphoma

Blood (2023) 142 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2023-179478

Published: 2023

Journal Articles

Real-World Impact of Differences in the World Health Organization (WHO) Classification and International Consensus Classification (ICC) Systems on the Diagnosis of Non-Hodgkin Lymphoma: An Analysis from the LEO Cohort Study

Blood (2023) 142 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2023-179303

Published: 2023

Journal Articles

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma

Matthew J. Maurer, Arushi Khurana, Raphael Mwangi, Grzegorz S. Nowakowski, Carla Casulo, Dai Chihara, Jonathon B. Cohen, Brad S. Kahl, Izidore S. Lossos, Peter Martin, Yucai Wang, Timothy J. McDonnell, Andrew L. Feldman, David L Jaye, Thomas M. Habermann, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Loretta J. Nastoupil

Blood (2023) 142 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2023-174715

Published: 2023

NARROW

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6 ) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

The FLIPI24 Prognostic Model Identifies Poor Outcomes in Non-Immunochemotherapy Treated Patients with Follicular Lymphoma

Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma - a Phase 2 Study

The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma

Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

LEO Consortium for Real World Evidence (CReWE): Outcomes after Second-Line Therapy in Large B-Cell Lymphoma By Treatment Era

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Risk of Transformation By Frontline Management in Follicular Lymphoma and Marginal Zone Lymphoma: A US Population-Based Analysis

A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Predictors and Timing of Venous Thromboembolism in Lymphoma

Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study

Cumulative Incidence, Predictors, and Outcomes of Transformation to Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Patients with Marginal Zone Lymphoma

PET/CT Enables Appropriate Staging in Extranodal Marginal Zone Lymphoma

Real-World Impact of Differences in the World Health Organization (WHO) Classification and International Consensus Classification (ICC) Systems on the Diagnosis of Non-Hodgkin Lymphoma: An Analysis from the LEO Cohort Study

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only